XML 49 R40.htm IDEA: XBRL DOCUMENT

Contingent consideration - non-current (Tables)

6 Months Ended

Dec. 31, 2022

Text block [abstract]

Summary of liabilities - contingent consideration


		Consolidated
		December				June 2022
		2022				Restated *
		$				$
Contingent consideration - Paxalisib			600,588				1,167,536
Contingent consideration - EVT801			7,517,729				7,041,409


			8,118,317				8,208,945

Summary of reconciliation of contingent consideration


		Consolidated
		December				June 2022
		2022				Restated *
		$				$
Reconciliation of the balance at the beginning and end of the reporting period is set out below:
Contingent consideration at start of period (current and non-current)			8,967,785				11,094,441
Payment of EVT801 milestone			—				(2,364,732	)
Interest			221,637				414,662
Foreign currency loss			282,130				(328,873	)
Loss on revaluation of contingent consideration			85,226				152,287


			9,556,778				8,967,785